Medeor is on path to making long-lasting immune tolerance a reality. We are conducting a pivotal Phase 3 clinical trial of a pioneering kidney transplant program.

HLA-matched Living donor kidney transplant (LDKT) Our lead product candidate is MDR-101, a cellular therapy manufactured from a living kidney donor’s blood and bone marrow cells. The …

What began more than 20 years ago at Stanford University has evolved into a promising biomedical platform that has helped to enable pivotal immunotherapy clinical trials with …

For hematologic conditions, mixed chimerism has the potential to reduce or eliminate disease symptoms. Medeor Therapeutics is the recipient of a grant by California Institute for …

Nov 2, 2023 · Medeor Therapeutics is working to improve the lives of transplant patients by eliminating or minimizing the need for a life-long regimen of immunosuppressive medications …

CP Liu, PhD has served on Medeor’s board since February 2019, and continues to serve as the chairman of the board for Tranquis Therapeutics, an early-stage biotechnology company …

Our technology platform is based on mixed chimerism, which is the coexistence of two different genotypes of cells―recipient and donor blood and immune cells―in the recipient. A platform …

He has also founded or co-founded a number of biopharmaceutical companies including Genelabs, Dendreon, Bolt and Tranquis, in addition to Medeor.

Medeor Therapeutics was cofounded in 2012 by Stanford University School of Medicine professors Drs. Samuel Strober, Edgar Engleman, Robert Lowsky; and entrepreneur Chih …

Sep 22, 2020 · Medeor Therapeutics Announces Interim Data from Pivotal Trial Showing Cell Therapy Technology Could Eliminate Life-Long Need for Immunosuppressant Drugs Following …